Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes

An acute coronary syndrome (ACS) event is associated with a high risk of recurrent ACS, stroke, and death. To ameliorate the risk of subsequent events, current guidelines for ST-segment elevation myocardial infarction and non-STsegment elevation ACS recommend long-term management strategies for secondary prevention including risk factor modification and anti-ischemic and antiplatelet therapies. Dual antiplatelet therapy (DAPT), comprising aspirin plus a P2Y(12) inhibitor, is a critical component of secondary prevention therapy following ACS. However, despite the importance of DAPT for secondary prevention after ACS, questions remain over the optimal duration of therapy. Clinical evidence is emerging that maintenance DAPT > 12 months lowers the risk of recurrent ACS events; however, this benefit must be considered against any potential risks of prolonged DAPT such as bleeding. Several tools for bleeding risk assessment have shown promise; however, their limited accuracy and discriminative power necessitates further development. Assessment of patient ischemic risk should consider the complexity of the percutaneous coronary intervention (PCI) procedure, anatomic burden of coronary artery disease, and additional underlying risk factors. Consequently, identifying patients in whom the risk:benefit ratio favors prolonged DAPT may prove invaluable for clinicians in deciding which patients should continue or stop taking DAPT at 12 months after PCI, or consider P2Y(12) inhibitor monotherapy as an option. This article reviews the most recent information about the risks and benefits of DAPT continued for > 12 months after ACS and provides critical guidance to assist physicians in identifying patients most likely to benefit from a secondary prevention strategy with DAPT.

Automated summary

An acute coronary syndrome (ACS) event is associated with a high risk of recurrent ACS, stroke, and death. Current guidelines recommend long-term management strategies for secondary prevention, but optimal duration of therapy is still a question. Emerging clinical evidence suggests that maintaining dual antiplatelet therapy (DAPT) for more than 12 months lowers the risk of recurrent ACS events, but potential risks of prolonged DAPT must be considered.